Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) regularly issues news on its RNA interference (RNAi) pipeline, regulatory milestones, clinical data, and capital markets activity. This ARWR news page on Stock Titan aggregates those updates so readers can follow how the company’s gene-silencing therapeutics are progressing across cardiometabolic, obesity, and neurodegenerative indications.
Recent company announcements highlight approvals and regulatory actions for REDEMPLO (plozasiran), a small interfering RNA medicine targeting apoC-III for adults with familial chylomicronemia syndrome (FCS). Arrowhead has reported approvals for REDEMPLO in the United States, Canada, and China, as well as Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia and ongoing Phase 3 trials in broader triglyceride disorders.
News items also cover interim clinical data for investigational obesity candidates ARO-INHBE and ARO-ALK7, which the company is studying for effects on visceral fat, total fat, liver fat, and body weight, including in obese patients with type 2 diabetes mellitus. Additional coverage includes the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies such as Alzheimer’s disease, using a TRiM-based delivery system intended to reach the central nervous system after subcutaneous administration.
Investors and observers will also find Arrowhead’s press releases on public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032, as well as collaboration and licensing updates such as the agreement with Novartis for ARO-SNCA and arrangements involving Visirna Therapeutics and Sanofi in Greater China. Bookmark this page to review Arrowhead’s earnings-related 8-K references, conference participation, and ongoing disclosures about its RNAi programs and commercial activities.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) received a positive CHMP opinion recommending approval of REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). The CHMP based its opinion on Phase 3 PALISADE data showing a median 80% triglyceride reduction and fewer acute pancreatitis cases versus placebo. The European Commission decision is expected in Q2 2026; REDEMPLO is self-administered subcutaneously every three months and carries known adverse reactions including hyperglycaemia (12.8%).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will webcast its fiscal 2026 second quarter results on May 7, 2026 at 4:30 p.m. ET. The company will host a live audio webcast and conference call to discuss results for the quarter ended March 31, 2026.
Investors can access the live webcast on Arrowhead's Events and Presentations page; a replay will be available about two hours after the call. Analysts must register to receive dial-in details and a personalized PIN to join the conference call.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported two-year open-label extension data for plozasiran in hypertriglyceridemia presented at ACC.26 on March 28, 2026. Patients with severe HTG saw a median -83% triglyceride reduction; 96% achieved TG <500 mg/dL. No adjudicated acute pancreatitis events occurred across the 2-year OLE.
Durable reductions were also observed in remnant cholesterol, non-HDL cholesterol, and ApoB with a safety profile consistent with earlier trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple investor events in March 2026, including TD Cowen, Leerink, Jefferies Biotech on the Beach, and Barclays conferences.
Scheduled appearances include fireside chats, investor dinners, and 1x1 meetings between March 2–11, 2026; presentation materials and webcasts will be posted on the company's Investors Events and Presentations page.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal 2026 first quarter results for the period ended December 31, 2025, and hosted a conference call on February 5, 2026. Key developments include FDA approval and U.S. launch of REDEMPLO for familial chylomicronemia syndrome, additional approvals in China and Canada, initiation of multiple Phase 1/2a trials, encouraging obesity interim data, and strengthened liquidity from concurrent public offerings.
Selected financials: Revenue $264.0M, operating income $40.8M, net income attributable to Arrowhead $30.8M, total cash resources $916.6M, and proceeds of $930.0M from public financings.
ADT (NYSE: ADT) will join the S&P SmallCap 600 effective prior to the opening of trading on Feb 9, 2026, as part of index changes by S&P Dow Jones Indices. The rebalancing also adds Ciena (CIEN) to the S&P 500 and moves Arrowhead Pharmaceuticals (ARWR) into the S&P MidCap 400 on Feb 9; OneSpaWorld (OSW) joins the SmallCap 600 on Feb 10.
Dayforce was removed following an acquisition by Thoma Bravo, and Dynavax was deleted ahead of its pending acquisition by Sanofi.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a study of ARO-DIMER-PA, described as the first clinical RNAi candidate designed to silence two genes with one molecule (PCSK9 and APOC3) using Arrowhead's TRiM™ platform. Preclinical data in hyperlipidemic nonhuman primates showed potent lowering of PCSK9 and APOC3 and reductions in non-HDL cholesterol, LDL-C, and triglycerides. The study advances Arrowhead's cardiometabolic RNAi portfolio alongside approved REDEMPLO and ongoing programs.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a live webcast and conference call on February 5, 2026 at 4:30 p.m. ET to discuss fiscal 2026 first quarter results for the period ended December 31, 2026. Investors can access the live audio webcast via the company's Events and Presentations page under Investors. A replay will be available approximately two hours after the call ends. Analysts wishing to join the conference call must register to receive a dial-in number and a personalized PIN to access the call.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) priced concurrent offerings: $625,000,000 aggregate 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock at $64.50 per share (or up to 1,550,387 pre-funded warrants at $64.499 each). Note settlement is scheduled for January 12, 2026; equity settlement is scheduled for January 9, 2026. Net proceeds are estimated at approximately $608.2M from notes and $188.3M from the common stock offering (pro forma higher if underwriters exercise options). Initial conversion rate is 11.4844 shares per $1,000 principal (≈$87.07 conversion price), and capped calls have an initial cap price of ≈$119.33 per share.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced NMPA approval of REDEMPLO (plozasiran) for reducing triglyceride levels in adults with familial chylomicronemia syndrome (FCS) in China on January 7, 2026.
Under an agreement with Sanofi, Sanofi will market REDEMPLO in Greater China and the NMPA approval triggers a $10 million milestone payment to Arrowhead subsidiary Visirna Therapeutics. This is REDEMPLO’s third regulatory approval following approvals by the U.S. FDA and Health Canada. REDEMPLO is a siRNA therapy administered by subcutaneous injection once every three months.